$Immuneering (IMRX.US)$ Here's my take: the stock's intrinsic worth ties to IMM-1-104's odds of making it big.
Pancreatic cancer's a tough market, but the data so far-50% response rate, plans for broader trials-looks promising. If we ballpark a 30-50% chance of approval by 2027-2028, and assume a modest $500 million peak sales potential (conservative for a cancer drug), a discounted cash flow might justify $5-8 per share today, factoring in dilution and risk.
Compare that to peers-say, small onco...

$Immuneering (IMRX.US)$
OK, well this thing hit’s a dollar I’m in. I think it has potential but they keep pushing it down whoever I don’t know who sell it
I really don’t care whoever wants to sell, sell blah blah blah. I’m over it.
What’s just get this to a nickel whatever it takes to fucking start reversing it bullshit Jesus Christ

$Immuneering (IMRX.US)$ what happend with this stock gose 2.45 and bang 1.77 again.

$Immuneering (IMRX.US)$I feel truly grateful to have had the opportunity to invest in Immuneering (IMRX) at such an early stage. I firmly believe in the potential of this company and the groundbreaking work they’re doing. The drugs they’re developing have the capacity to make a significant difference in the lives of so many people, and that’s something I deeply resonate with. The results they’ve achieved so far are nothing short of incredible, and it fills me with immense hope and gratitude. I tr...

$Immuneering (IMRX.US)$ IMRX is bursting with potential, a stock teeming with endless possibilities across multiple realities! No matter which path you envision, they all lead to the same thrilling destination—upward momentum. The only question is, how high will it go? Buckle up!

$Immuneering (IMRX.US)$ $IMRX Immuneering isn’t just another biotech. They’re rewriting the rules of drug discovery using advanced bioinformatics, aiming to outsmart diseases at the molecular level. Their Deep Informatics Platform analyzes vast biological datasets to find hidden drug targets—essentially bringing AI-power
🧬 A New Kind of Drug Design: Unlike traditional drugs that hit their targets constantly, Immuneering’s “Deep Cyclic Inhibition” strategy uses pulsed dosing to give cancer cells j...

$Immuneering (IMRX.US)$Yes, Immuneering Corporation is scheduled to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. The presentation will take place from 2:40 PM to 3:10 PM Eastern Time (11:40 AM to 12:10 PM Pacific Time) in Track 2. During this virtual event, CEO Ben Zeskind and Chief Scientific Officer Brett Hall will discuss the company’s pipeline, platform, and business strategy. The presentation will be webcast live and archived in the Investo...

$Immuneering (IMRX.US)$ Immuneering Corporation (NASDAQ: IMRX) has received varied price targets from analysts, reflecting optimism about its potential. Currently trading at $1.86 per share, targets range from $8.00 to $25.00, with an average of around $12.00, suggesting significant upside. Notably, Needham reaffirmed a $12.00 target, and Mizuho initiated coverage with a $10.00 target. These figures indicate potential growth, but the broad range highlights uncertainties typical of developmental b...

$Immuneering (IMRX.US)$ Immuneering Corporation has announced a clinical supply agreement with Regeneron Pharmaceuticals to evaluate the combination of Immuneering’s lead product candidate, IMM-1-104, with Regeneron’s anti-PD-1 therapy, Libtayo (cemiplimab). This collaboration aims to assess the efficacy of this combination in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC) as part of Immuneering’s ongoing Phase 2a clinical trial.
Under the terms of the agr...

$Immuneering (IMRX.US)$
This partnership significantly enhances Immuneering's credibility in the oncology space, particularly valuable for a clinical-stage company with a market cap of $59.3 million. The collaboration with Regeneron, a major player in immuno-oncology, provides important validation for IMM-1-104's potential and could catalyze investor interest.
The structure of the agreement is particularly advantageous for Immuneering. By maintaining global development an...